Book a Meeting

Non-fucosylated Anti-Human CD80 (Galiximab) Therapeutic Antibody (CAT#: BioBet-165ZP) Datasheet

Target
CD80
Isotype
IgG1, λ
Description
ADCC-enhanced Galiximab is a non-fucosylated anti-CD80 therapeutic biobetter antibody.
Indication
Non-Hodgkin's lymphoma (NHL)
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD80 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD80
Full Name
CD80 Molecule
Background
CD80 (CD80 Molecule) is a Protein Coding gene.
Diseases associated with CD80 include Focal Segmental Glomerulosclerosis and Vaccinia.
Among its related pathways are PEDF Induced Signaling and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include coreceptor activity.
An important paralog of this gene is CD86.
Alternative Names
Galiximab; 357613-77-5; IDEC-114; 16C10; CD80; CD80 molecule; CD28LG, CD28LG1, CD80 antigen (CD28 antigen ligand 1, B7 1 antigen), CD80 molecule; T-lymphocyte activation antigen CD80; B lymphocyte activation antigen B7; B7 1; B7.1; activation B7-1 antigen;
Gene ID
941
UniProt ID
P33681
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with CD80 include Vaccinia and Focal Segmental Glomerulosclerosis.
Related Pathways
Its related pathways are Nur77 Signaling in T-Cell and RET signaling.
Function
Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.
Post-translational modifications
1.Glycosylation at Asn53, Asn89, Asn98, Asn186, Asn207, Asn211, Asn226, and Asn232 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, λ
Antibody Clone
Galiximab
Host
Chimeric
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD8. Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, The drug is a antibody from Macaca irus and Homo sapiens.
Indication
Non-Hodgkin's lymphoma (NHL)

Non-Hodgkin's lymphoma (NHL)

Related Products

BetterBet™ Anti-CD80 Recycling Antibody (CAT#: AES-0622-ZP133)
BetterBet™ Anti-CD80 On-Target Antibody (CAT#: AES-0622-ZP789)
BetterBet™ Anti-CD80 Half-Life Extended Antibody (CAT#: AES-0622-ZP1117)
Non-Fucosylated Anti-Human CD80 (L104EA29YIg) Therapeutic Antibody (CAT#: BioBet-684ZP)
Highly Galactosylated Anti-CD80 (Galiximab) Antibody (CAT#: BioBet-GA-165ZP)
BetterBet™ Anti-CD80 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP461)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany